Formycon 的 Ranibizumab 生物仿制药 FYB201/Ravegza 获得沙特营销授权，并计划于 2024 年在中东和北非地区扩张。 Formycon's Ranibizumab biosimilar, FYB201/Ravegza, receives Saudi marketing authorization and plans to expand in the MENA region in 2024.
Formycon AG 的 FYB201/Ranibizumab 是 Lucentis® 的生物仿制药，获得沙特食品药品管理局的营销授权后势头强劲。 Formycon AG's FYB201/Ranibizumab, a biosimilar to Lucentis®, gains momentum with Saudi Food & Drug Authority's marketing authorization. 继在约旦成功推出市场并赢得沙特阿拉伯政府招标后，FYB201/Ravegza® 计划于 2024 年第二季度推出。 Following a successful market launch in Jordan and winning a government tender in Saudi Arabia, the launch of FYB201/Ravegza® is planned in the second quarter of 2024. 计划在 2024 年进一步推出，以改善中东和北非地区获得眼科治疗的机会。 Further launches are planned throughout 2024 to improve access to ophthalmic treatments in the MENA region.